A four-year clinical investigation led by Cleveland-based cardiologist Dr. Sarah Mitchell suggests that many women over 50 struggle with belly fat due to declining GLP-1 hormone levels rather than a lack of willpower or caloric intake. Dr. Mitchell's research, which involved reviewing lab work from 217 women, indicates that the body's natural ability to signal satiety and burn fat decreases significantly after age 50.
Dr. Mitchell found that up to 67% lower average GLP-1 levels in women over 50 compared to women in their 30s may drive persistent abdominal weight gain. GLP-1 is a hormone produced in the gut that tells the brain the body is full, slows digestion, and signals the release of stored fat.
While prescription GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro are available, they often come with high out-of-pocket costs ranging from $900 to $1,400 per month, and may cause side effects such as nausea, vomiting, and muscle loss. Additionally, research indicates that up to 67% of patients may regain weight within 12 months of discontinuing these drugs.
In response to patient needs, Dr. Mitchell explored alternatives and identified a transdermal delivery system developed by a California biotech lab. Sold under the name Evelmont, this patch uses plant-derived compounds to support the body's natural GLP-1 pathway through the skin over an 8 to 12-hour period.
Dr. Mitchell reported that the patch bypasses the digestive system, potentially avoiding the loss of active compounds to stomach acid. In a tracking of 47 patients between ages 49 and 67, 86% reported visible belly fat reduction within 90 days, with an average weight loss of 17.4 pounds among responders.
The Evelmont patch is currently sold directly by the manufacturer rather than in pharmacies or through third-party retailers. The product is priced at $69 for a 30-day supply, with promotional bundles available for longer durations. The manufacturer offers a 60-day money-back guarantee on the product.
